ASND
Ascendis Pharma A/S
Next earnings Aug 5, 2026 (after close) · consensus $1.43 EPS, $339M rev
$274.50
▲ +4.10%$274.50▲ +59.39%
over 1Y
L $163.32H $274.50
Today+4.1%
1W+4.9%
1M+26.7%
3M+19.7%
YTD+28.7%
1Y+59.4%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 26 analysts
Strong Buy
Mixed signals in the latest filings.
Ascendis Pharma A/S shows limited reported revenue.
On these fundamentals, ASND screens as SELL on the SEC figures.
Is ASND a buy? The one-page verdict, explained →
The options angle
model · matches our verdictBear put spread~60d expiry
- Long put 275 @ ~19.89 est
- Short put 245 @ ~7.70 est
debit $1,219max +$1,781max −$1,219BE 262.81
SELL verdict, defined risk: profits into weakness down to the short strike; max loss is the net debit.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Financials · annual, by fiscal year
No income data filed.
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$18.0B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt—
Net cash—
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+2.1%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Recent filings
all on EDGAR ↗6-KPeriod ending 2026-06-302026-06-30open ↗6-KPeriod ending 2026-06-292026-06-29open ↗6-KPeriod ending 2026-06-172026-06-17open ↗6-KPeriod ending 2026-06-152026-06-15open ↗6-KPeriod ending 2026-06-122026-06-12open ↗6-KPeriod ending 2026-06-102026-06-10open ↗4Period ending 2026-06-022026-06-02open ↗4Period ending 2026-05-292026-06-01open ↗4Period ending 2026-05-292026-06-01open ↗3/APeriod ending 2026-03-182026-06-01open ↗4Period ending 2026-05-262026-05-27open ↗SDFiling2026-05-22open ↗
Frequently asked
- Is Ascendis Pharma A/S (ASND) a buy?
- ASND currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.
- What is Ascendis Pharma A/S's quality score?
- ASND scores 94.09556313993176/100 (grade A+) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001612042, latest 6-K filed 2026-06-30) · EODHD · as of 7/4/2026, 9:57:06 PM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 4, 2026, 5:57 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.